Literature DB >> 27354022

Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis.

Krisstina Gowin1, Maria Coakley2, Heidi Kosiorek3, Ruben Mesa4.   

Abstract

Entities:  

Keywords:  post essential thrombocytosis myelofibrosis; post polycythemia vera; primary myelofibrosis; prognostic scores

Mesh：

Year:  2016        PMID： 27354022      PMCID： PMC5046661          DOI： 10.3324/haematol.2016.149013

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2010-10-14       Impact factor: 22.113

2.  A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.

Authors:  Francesco Passamonti; Elisa Rumi; Marianna Caramella; Chiara Elena; Luca Arcaini; Emanuela Boveri; Cecilia Del Curto; Daniela Pietra; Laura Vanelli; Paolo Bernasconi; Cristiana Pascutto; Mario Cazzola; Enrica Morra; Mario Lazzarino
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

Review 3.  Pathogenesis of myelofibrosis with myeloid metaplasia.

Authors:  Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2005-11-20       Impact factor: 44.544

Review 4.  The evolution and clinical relevance of prognostic classification systems in myelofibrosis.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Cancer       Date:  2015-12-30       Impact factor: 6.860

5.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

Authors:  Naseema Gangat; Domenica Caramazza; Rakhee Vaidya; Geeta George; Kebede Begna; Susan Schwager; Daniel Van Dyke; Curtis Hanson; Wenting Wu; Animesh Pardanani; Francisco Cervantes; Francesco Passamonti; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

6.  Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.

Authors:  B Dupriez; P Morel; J L Demory; J L Lai; M Simon; I Plantier; F Bauters
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

7.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

8.  CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.

Authors:  A Tefferi; P Guglielmelli; T L Lasho; G Rotunno; C Finke; C Mannarelli; A A Belachew; A Pancrazzi; E A Wassie; R P Ketterling; C A Hanson; A Pardanani; A M Vannucchi
Journal:  Leukemia       Date:  2014-02-05       Impact factor: 11.528

9.  Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.

Authors:  Giada Rotunno; Annalisa Pacilli; Valentina Artusi; Elisa Rumi; Margherita Maffioli; Federica Delaini; Giada Brogi; Tiziana Fanelli; Alessandro Pancrazzi; Daniela Pietra; Isabella Bernardis; Clara Belotti; Lisa Pieri; Emanuela Sant'Antonio; Silvia Salmoiraghi; Daniela Cilloni; Alessandro Rambaldi; Francesco Passamonti; Tiziano Barbui; Rossella Manfredini; Mario Cazzola; Enrico Tagliafico; Alessandro M Vannucchi; Paola Guglielmelli
Journal:  Am J Hematol       Date:  2016-05-11       Impact factor: 10.047

10.  Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage.

Authors:  Leonardo Boiocchi; Susan Mathew; Umberto Gianelli; Alessandra Iurlo; Tommaso Radice; Sharon Barouk-Fox; Daniel M Knowles; Attilio Orazi
Journal:  Mod Pathol       Date:  2013-06-21       Impact factor: 7.842
  10 in total
  8 in total

Review 1.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

2.  Survival following allogeneic transplant in patients with myelofibrosis.

Authors:  Krisstina Gowin; Karen Ballen; Kwang Woo Ahn; Zhen-Huan Hu; Haris Ali; Murat O Arcasoy; Rebecca Devlin; Maria Coakley; Aaron T Gerds; Michael Green; Vikas Gupta; Gabriela Hobbs; Tania Jain; Malathi Kandarpa; Rami Komrokji; Andrew T Kuykendall; Kierstin Luber; Lucia Masarova; Laura C Michaelis; Sarah Patches; Ashley C Pariser; Raajit Rampal; Brady Stein; Moshe Talpaz; Srdan Verstovsek; Martha Wadleigh; Vaibhav Agrawal; Mahmoud Aljurf; Miguel Angel Diaz; Belinda R Avalos; Ulrike Bacher; Asad Bashey; Amer M Beitinjaneh; Jan Cerny; Saurabh Chhabra; Edward Copelan; Corey S Cutler; Zachariah DeFilipp; Shahinaz M Gadalla; Siddhartha Ganguly; Michael R Grunwald; Shahrukh K Hashmi; Mohamed A Kharfan-Dabaja; Tamila Kindwall-Keller; Nicolaus Kröger; Hillard M Lazarus; Jane L Liesveld; Mark R Litzow; David I Marks; Sunita Nathan; Taiga Nishihori; Richard F Olsson; Attaphol Pawarode; Jacob M Rowe; Bipin N Savani; Mary Lynn Savoie; Sachiko Seo; Melhem Solh; Roni Tamari; Leo F Verdonck; Jean A Yared; Edwin Alyea; Uday Popat; Ronald Sobecks; Bart L Scott; Ryotaro Nakamura; Ruben Mesa; Wael Saber
Journal:  Blood Adv       Date:  2020-05-12

Review 3.  Myeloproliferative neoplasms: from origins to outcomes.

Authors:  Jyoti Nangalia; Anthony R Green
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.

Authors:  Lucia Masarova; Prithviraj Bose; Naval Daver; Naveen Pemmaraju; Kate J Newberry; Taghi Manshouri; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2017-06-02       Impact factor: 3.156

5.  CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis.

Authors:  Mariam T Nawas; Jeong-Ok Lee; Jessica Flynn; Molly Maloy; Ann A Jakubowski; Esperanza B Papadopoulos; Christina Cho; Doris M Ponce; Craig S Sauter; Miguel-Angel Perales; Sean Devlin; Sergio A Giralt; Hugo R Castro-Malaspina; Roni Tamari
Journal:  Bone Marrow Transplant       Date:  2022-04-28       Impact factor: 5.174

Review 6.  Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.

Authors:  Francesco Passamonti; Barbara Mora; Daniela Barraco; Margherita Maffioli
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 7.  MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment.

Authors:  Julian Grabek; Jasmin Straube; Megan Bywater; Steven W Lane
Journal:  Cells       Date:  2020-08-14       Impact factor: 6.600

Review 8.  Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.

Authors:  Ruth Stuckey; María Teresa Gómez-Casares
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.